Ekso Bionics(TM) to Host Fourth Quarter and Year End

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Ekso Bionics(TM) to Host Fourth Quarter and Year End Financial Results Conference Call on Tuesday, March 17th, 2015

RICHMOND, Calif., March 11, 2015 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company today announced that it will host a conference call and audio webcast to discuss fourth quarter and year end results, as well as provide a general business update, on Tuesday, March 17th, 2015 at 4:30pm ET.

Conference call and webcast details:

Date: March 17 th , 2015


Time: 4:30pm ET  


Listen via Internet: http://eksobionics.equisolvewebcast.com/q4-2014

Dial-In (Toll-Free US & Canada):  877-407-3036


Dial-In (International):  201-378-4919

Replay Information:

Conference ID #:  13581989


Replay Dial-In (Toll Free US & Canada):  877-660-6853


Replay Dial-In (International):  201-612-7415


Expiration Date:  3/31/15

Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible.

Ekso Bionics' lead product, Ekso TM , is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.

About Ekso Bionics (OTCQB:EKSO)

Since 2005, Ekso Bionics ( http://www.eksobionics.com ) has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Facebook: www.facebook.com/eksobionics
Twitter: @eksobionics
YouTube: http://www.youtube.com/user/EksoBionics/

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of financial results, financial condition, capital expenditures, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing to fund the Company's operations and necessary to develop or enhance our technology, the significant length of time and resources associated with the development of the Company's products, the Company's failure to achieve broad market acceptance of the Company's products, the failure of our sales and marketing organization or partners to market our products effectively, adverse results in future clinical studies of the Company's medical device products, the failure to obtain or maintain patent protection for the Company's technology, failure to obtain or maintain regulatory approval to market the Company's medical devices, lack of product diversification, existing or increased competition, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. To learn more about Ekso Bionics please visit us at  www.eksobionics.com . The Company does not undertake to update these forward-looking statements.

Media Contact: Heidi Darling, Director of Marketing Communications Phone: 415.302.4777 Investor Contact: John Graziano, The Trout Group Phone: 646.378.2942

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Happiest Minds Extends Absa Banking Platform Reach

Updated Category News Views 34

Mauritius just handed Happiest Minds a useful, if modest, banking-tech scorecard. On November 19, 2026, the company said its cloud-native Arttha platform had been deployed to support selected capabilities within Spark by Absa, a digital banking and lifestyle app from Absa Bank (Mauritius). This is not the sort of announcement that lets anybody pencil in a giant revenue...

Continue Reading
California Budget Warning Puts Reserves Back in Focus

Updated Category News Views 118

California’s rainy-day umbrella is getting another hard look, and it should. State Controller Malia M. Cohen is pointing to the Legislative Analyst’s Office fiscal outlook as a reminder that budget discipline and stronger reserves are not ornamental good-government phrases. They are the difference between absorbing a revenue wobble and reaching for ugly fixes after...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 0

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 34

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Youdao Sets December AGM With No Vote on the Table

Updated Category News Views 74

A shareholder meeting without a vote is more temperature check than showdown, and that is exactly what Youdao has scheduled for December 17, 2026. The company will gather shareholders from 3:00 p.m. to 5:00 p.m. Beijing time at its Beijing office, but it has made one point painfully clear: no proposal will be submitted for shareholder approval. For holders of NYSE: DAO,...

Continue Reading
JOYY Q3 Growth Shows More Than Livestreaming Muscle

Updated Category News Views 39

Revenue finally has more than one pair of legs at JOYY, and that matters a whole lot more than a flashy quarterly headline. The company reported third-quarter 2026 revenue of US$624.6 million, up 15.6% from a year earlier and 5.7% from the prior quarter. Those are not microscopic moves, and the composition is the part that deserves the hard stare. JOYY is still rooted in...

Continue Reading
A Hybrid Book Bets on Muscles, Myth, and Machines

Updated Category News Views 66

Few publishing pitches ask readers to carry a barbell into Tartarus, but A R Quigley is plainly not chasing the middle of the bookstore. Doctrina Machina Learning Machine, released by Palmetto Publishing in November 2026, welds together a strength-training guide and an underground military science-fiction war story. That is an odd little contraption, no use pretending...

Continue Reading
Innoviz's 1-for-20 Split Is a Listing Lifeline Test

Updated Category News Views 93

A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...

Continue Reading
SAGA's Radar Assays Tighten the Trapper North Case

Updated Category News Views 188

Rock that keeps showing up where the model says it should is the sort of boring news a junior miner desperately needs. SAGA Metals has put out fresh assay results from Radar’s Trapper North area, and the useful part is not merely a loud grade in one hole. It is the apparent persistence of thick titanium-vanadium-iron oxide mineralization across tighter-spaced drilling....

Continue Reading
Scenthound’s Franchise Award Spotlights a Real Test

Updated Category News Views 169

A clean dog may not sound like a growth story, yet Scenthound has turned that neglected chore into a surprisingly serious franchise proposition. The company has won the International Franchise Association’s Emerging Franchisor Award after building its dog-hygiene concept from a 2015 founding into a network with more than 180 open locations. That is a respectable piece...

Continue Reading

Top 5 Most Recently Viewed Articles

Melissa Tapanes Llahues Takes Charge as BASF President

Updated Category News Views 200

Melissa Tapanes Llahues Installed as President of BASF Bercow Radell Fernandez Larkin & Tapanes Partner continues her leadership across the development sectors Melissa Tapanes Llahues, an esteemed land use attorney and civic leader, has been officially installed as President of the Builders Association of South Florida (BASF), a key player in the region's development...

Continue Reading
Petco's Q2 2025 Results: A Look at Performance and Projections

Updated Category News Views 217

Petco's Q2 2025 Financial Results Overview Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) has revealed its financial performance for the second quarter of 2025, showcasing various achievement metrics and prospects for the remainder of the fiscal year. With a commitment to ongoing improvement, Petco has raised its earnings outlook and emphasized a strong economic...

Continue Reading
Empowering Women in STEM: A Transformative Networking Opportunity

Updated Category News Views 309

Empowering Women in STEM: A Transformative Networking Opportunity On November 12, a groundbreaking event titled "Connecting Our Talents; Women in STEM" will take place, bringing together female STEM students from various educational institutions. This event aims to highlight emerging talents and connect them with industry professionals, creating an invaluable network for...

Continue Reading
Analyzing Market Sentiment for Simpson Manufacturing Co Inc.

Updated Category News Views 260

Understanding Market Sentiment for Simpson Manufacturing Co Inc Simpson Manufacturing Co Inc's (NYSE: SSD) short interest has experienced a notable increase, with reports indicating a surge of 6.31% since the latest update. Currently, approximately 1.10 million shares have been sold short, which accounts for about 3.37% of the total shares available for trading. This...

Continue Reading
Growth of Hemp-Based Foods Market: Insights and Trends

Updated Category News Views 104

The Hemp-Based Foods Market: A Growing Trend The hemp-based foods market is experiencing remarkable growth, with projections indicating it will hit $10.6 billion by 2033. This marks a significant increase from $5.4 billion in 2023, boasting a compound annual growth rate (CAGR) of 7.2%. This upward trend shows a clear shift in consumer preferences toward plant-based diets,...

Continue Reading